Takeda Pharmaceutical Co. Ltd. Sponsored ADR Aktie News

Takeda Pharmaceutical Company Limited ( TAK ) Q2 2026 Earnings Call October 30, 2025 6:00 AM EDT Company Participants Christopher David O'Reilly - Global Head of Investor Relations & Global Finance Christophe Weber - President, CEO & Representative Director Milano Furuta - CFO & Director Andrew Plump - President of Research & Development and Representative Director Teresa Bitetti - President of...

OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the first half of fiscal year 2025 (six months ended Sep 30, 2025) and updated its full-year outlook. Takeda chief executive officer, Christophe Weber, commented: “Takeda's fiscal year 2025 first half results are consistent with our expectations for core business progress in this year of transition ...

Takeda Pharmaceutical Company Limited (NYSE:TAK ) Discusses Global Strategic Collaboration for Next-Generation Oncology Assets and ADC Molecules October 22, 2025 9:00 AM EDT Company Participants Zhengwei Song - Director of IR & Financial Strategy De-Chao Yu - Co-Founder, Chairman & CEO Samuel Suhua Zhang - Global Chief Business Officer Hui Zhou - Chief R&D Officer for Oncology Phuong Morrow - H...

The tie-up is the latest between Chinese companies and international pharma majors looking to expand their global reach and tap promising drug pipelines developing in China.

China's Innovent Biologics said on Wednesday it had signed an $11.4 billion deal with Japan's Takeda Pharmaceutical Co to accelerate the development of its immuno-oncology and antibody-drug conjugate cancer therapies.

The collaboration combines Innovent's proven immuno-oncology ("IO") and antibody-drug conjugate ("ADC") R&D capability and Takeda's experience in global oncology drug development to accelerate Innovent's two late-stage investigational medicines worldwide, and Takeda receives an option for an early-stage program. Innovent and Takeda will co-develop the IO backbone therapy IBI363 (PD-1/IL-2α-bias...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that it has entered into a license and collaboration agreement with Innovent Biologics (HKEX: 01801) for the development, manufacturing and commercialization of two late-stage oncology medicines, IBI363 and IBI343, worldwide outside of Greater China.* IBI363 is being evaluated in non-small cell lung and...

U.S. biotech firm Nabla Bio said on Tuesday it has signed a second major research partnership with Japanese drugmaker Takeda Pharmaceutical , deepening their use of artificial intelligence to accelerate drug discovery.